Article
Multimodality therapy with a replication-conditional herpes simplex virus 1 mutant that expresses yeast cytosine deaminase for intratumoral conversion of 5-fluorocytosine to 5-fluorouracil.
Cancer research - 15 Jul 2001
Nakamura H, Mullen J T, Chandrasekhar S, Pawlik T M, Yoon S S, Tanabe K K
Abstract excerpt
Infection of tumor cells by herpes simplex virus 1 (HSV-1) results in cell destruction and production of progeny virion in a process referred to as viral oncolysis. In this study, an HSV-1 mutant (HSV1yCD) was engineered such that the viral ribonucleotide reductase gene is disrupted by sequences encoding yeast cytosine deaminase, which efficiently metabolizes the prodrug 5-fluorocytosine (5-FC) to 5-fluorouracil...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.